Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
AbbVie
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04578756CT.gov Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autism Spectrum Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cariprazine (this asset) | AbbVie | P3 | BB · 64 |
| Metformin | Holland Bloorview Kids Rehabilitation Hospital | P4 | BBB |
| Risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P4 | BB |
| Lumateperone | Intra-Cellular Therapies, Inc. | P3 | B |
| Karxt | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | P3 | B |
| Lurasidone | University of North Carolina, Chapel Hill | P2 | B |
| Betahistine | Nathan Kline Institute for Psychiatric Research | P2 | B |
| Alpha-Tocotrienol Quinone | Edison Pharmaceuticals Inc | P2 | CCC |
| Sertraline | Holland Bloorview Kids Rehabilitation Hospital | P2 | CCC |
+7 more in the Autism Spectrum Disorder cohort
Other indications for Cariprazine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar I Disorder | — | P4 | BBB · 73 |
| Schizophrenia | — | P3 | BB · 70 |
| Major Depressive Disorder | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cariprazine in Autism Spectrum Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cariprazine-autism-spectrum-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →